Table 7.
Grading of Recommendations Assessment, Development and Evaluation (GRADE) evidence profile for population, intervention, comparison, outcome 22: Tixagevimab-cilgavimab for mild or moderate coronavirus disease 2019
| People: Patients with mild or moderate COVID-19 Settings: Ambulatory patients Intervention: Tixagevimab-cilgavimab at 300 mg + 300 mg administered via intramuscular injections Comparison: No treatment | |||||
|---|---|---|---|---|---|
| Outcomes |
Absolute effect |
Relative effect (95% CI) |
Number of studies |
Certainty of the evidence (GRADE) |
|
| With tixagevimab-cilgavimab | Without tixagevimab-cilgavimab | ||||
| All-cause mortality (within 29 d from treatment) | 6/452 (1%) | 6/451 (1%) | RR: 1.00 (0.32–3.06) | 1 [60] (903 patients) | ⊕⊕⊖⊖ Low (due to very serious imprecision) |
| Difference: 0 fewer per 1000 (95% CI: −61 to 60) | |||||
| Hospitalisation (within 29 d from treatment) | 18/407 (4%) | 37/415 (9%) | RR: 0.49 (0.28–0.85) | 1 [60] (822 patients) | ⊕⊕⊕⊖ Moderate (due to serious imprecision) |
| Difference: 22 fewer per 1000 (95% CI: −12 to −91) | |||||
| Adverse events (end of follow-up) | 132/452 (29%) | 163/451 (36%) | RR: 0.80 (0.66–0.97) | 1 [60] (903 patients) | ⊕⊕⊕⊖ Moderate (due to serious imprecision) |
| Difference: 14 fewer per 1000 (95% CI: −7 to −119) | |||||
COVID-19, coronavirus disease 2019; GRADE, Grading of Recommendations Assessment, Development and Evaluation; RR, risk ratio.